Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell‑based therapeutic interventions
Molecular Medicine Reports · 2025
DOI: 10.3892/mmr.2025.13694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, 2025. Verfasst von Qihang Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Cholesterol, Connexins, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cholesterol metabolism reprogramming serves a pivotal role in tumor onset and progression. The present study investigated lung adenocarcinoma (LUAD), focusing on the regulatory impact of cholesterol metabolism‑related genes (CMRGs). Consensus clustering identified distinct cholesterol metabolism‑related clusters in LUAD, followed by survival analysis and immune infiltration profiling for each cluster. A predictive model, constructed using cluster‑specific differentially expressed genes and the LASSO algorithm, was validated with an independent dataset. Furthermore, the model was utilized to predict potential responses to immunotherapy and chemotherapy for patients with LUAD. The functional role of the key gene GJB3 in LUAD progression was confirmed through in vitro experiments. Two distinct cholesterol metabolism‑related clusters were identified, exhibiting significant differences in prognosis, biological function and immune cell infiltration. A survival model, based on four genes, demonstrated strong predictive performance across multiple datasets. The low‑risk group showed improved responses to immunotherapy, while the high‑risk group exhibited heightened sensitivity to chemotherapy. In vitro assays revealed that GJB3 knockdown suppressed LUAD cell proliferation and invasion, significantly reducing the expression of epithelial‑mesenchymal transition‑related genes. These findings highlight CMRGs as potential prognostic biomarkers and suggest a foundation for personalized treatment strategies in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China.
- Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat‑sen University, Zhuhai, Guangdong 519000, P.R. China.
Zitieren
APA
Yan, Q., Chang, W., Wong, W., Gong, L., Liang, D., Yang, J., & Wang, J. (2025). Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell‑based therapeutic interventions. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2025.13694
Vancouver
Yan Q, Chang W, Wong W, Gong L, Liang D, Yang J, et al. Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell‑based therapeutic interventions. Molecular Medicine Reports. 2025. doi:10.3892/mmr.2025.13694
BibTeX
@article{Yan2025,
author = {Yan, Qihang and Chang, Wuguang and Wong, Wingshing and Gong, Li and Liang, Dachuan and Yang, Jie and Wang, Junye},
title = {Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell‑based therapeutic interventions},
journal = {Molecular Medicine Reports},
year = {2025},
doi = {10.3892/mmr.2025.13694}
}
EUVIMED